Category Archives: Stell Cell Research

Stem Cell Manufacturing Market 2021 | Research With Size, Growth, Manufacturers, Key Segment, Analysis, Development Status, Segments and 2027…

Global Stem Cell Manufacturing Market Report from DBMR highlights deep analysis on market characteristics, sizing, estimates and growth by segmentation, regional breakdowns& country along with competitive landscape, players market shares, and strategies that are key in the market. The exploration provides a 360 view and insights, highlighting major outcomes of the industry. These insights help the business decision-makers to formulate better business plans and make informed decisions to improved profitability. In addition, the study helps venture or private players in understanding the companies in more detail to make better informed decisions.

Stem cell manufacturing is forecasted to grow at CAGR of 6.42% to an anticipated value of USD 18.59 billion by 2027 with factors like rising awareness towards diseases like cancer, degenerative disorders and hematopoietic disorders is driving the growth of the market in the forecast period of 2020-2027.

Download Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on thisIndustry@

Stem cell manufacturing has shown an exceptional penetration in North America due to increasing research in stem cell. Increasing research and development activities in biotechnology and pharmaceutical sector is creating opportunity for the stem cell manufacturing market.

The Global Stem Cell Manufacturing Market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Stem Cell Manufacturing Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

Global Stem Cell Manufacturing Market Segematation By Product (Stem Cell Line, Instruments, Culture Media, Consumables), Application (Research Applications, Clinical Applications, Cell and Tissue Banking), End Users (Hospitals and Surgical Centers, Pharmaceutical and Biotechnology Companies, Clinics, Community Healthcare, Others)

List of TOP KEY PLAYERS in Stem Cell Manufacturing Market Report are

Thermo Fisher Scientific Merck KGaA BD JCR Pharmaceuticals Co., Ltd Organogenesis Inc Osiris Vericel Corporation AbbVie Inc AM-Pharma B.V ANTEROGEN.CO.,LTD Astellas Pharma Inc Bristol-Myers Squibb Company FUJIFILM Cellular Dynamics, Inc RHEACELL GmbH & Co. KG Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Ltd ViaCyte,Inc VistaGen Therapeutics Inc GlaxoSmithKline plc ..

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@

The report can help to understand the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Stem Cell Manufacturing industry. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Stem Cell Manufacturing manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The Global Stem Cell Manufacturing Market Trends, development and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Global Stem Cell Manufacturing Market Scope and Market Size

Stem cell manufacturing market is segmented on the basis of product, application and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on product, the stem cell manufacturing market is segmented into stem cell lines, instruments, culture media and consumables. Stem cell lines are further segmented into induced pluripotent stem cells, embryonic stem cells, multipotent adult progenitor stem cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells. Instrument is further segmented into bioreactors and incubators, cell sorters and other instruments.

On the basis of application, the stem cell manufacturing market is segmented into research applications, clinical applications and cell and tissue banking. Research applications are further segmented into drug discovery and development and life science research. Clinical applications are further segmented into allogenic stem cell and autologous stem cell therapy.

On the basis of end users, the stem cell manufacturing market is segmented into hospitals and surgical centers, pharmaceutical and biotechnology companies, research institutes and academic institutes, community healthcare, cell banks and tissue banks and others.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Stem cell manufacturing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for stem cell manufacturing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the stem cell manufacturing market. The data is available for historic period 2010 to 2018.

The Global Stem Cell Manufacturing Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of stem cell manufacturing market for global, Europe, North America, Asia Pacific and South America.

Key Insights in the report:

Historical and current market size and projection up to 2025

Market trends impacting the growth of the global taste modulators market

Analyze and forecast the taste modulators market on the basis of, application and type.

Trends of key regional and country-level markets for processes, derivative, and application Company profiling of key players which includes business operations, product and services, geographic presence, recent developments and key financial analysis

For More Information or Query or Customization Before Buying, Visit @

Opportunities in the market

To describe and forecast the market, in terms of value, for various segments, by region North America, Europe, Asia Pacific (APAC), and Rest of the World (RoW)

The key findings and recommendations highlight crucial progressive industry trends in the Stem Cell manufacturing Market, thereby allowing players to develop effective long term strategies

To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, and detail the competitive landscape for market leaders Extensive analysis of the key segments of the industry helps in understanding the trends in types of point of care test across Europe.

To get a comprehensive overview of the Stem Cell manufacturing market.

With tables and figures helping analyses worldwide Global Stem Cell Manufacturing Market Forecast this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. There are 15 Chapters to display the Stem Cell Manufacturing market.

Chapter 1, About Executive Summary to describe Definition, Specifications and Classification of Stem Cell Manufacturing market, By Product Type, by application, by end users and regions.

Chapter 2, objective of the study.

Chapter 3, to display Research methodology and techniques.

Chapter 4 and 5, to show the Stem Cell Manufacturing Market Analysis, segmentation analysis, characteristics;

Chapter 6 and 7, to show Five forces (bargaining Power of buyers/suppliers), Threats to new entrants and market condition;

Chapter 8 and 9, to show analysis by regional segmentation[North America, Europe, Asia-Pacific etc ], comparison, leading countries and opportunities; Regional Marketing Type Analysis, Supply Chain Analysis

Chapter 10, to identify major decision framework accumulated through Industry experts and strategic decision makers;

Chapter 11 and 12, Stem Cell Manufacturing Market Trend Analysis, Drivers, Challenges by consumer behavior, Marketing Channels

Chapter 13 and 14, about vendor landscape (classification and Market Ranking)

Chapter 15, deals with Stem Cell Manufacturing Market sales channel, distributors, Research Findings and Conclusion, appendix and data source.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand]

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475


See the article here:
Stem Cell Manufacturing Market 2021 | Research With Size, Growth, Manufacturers, Key Segment, Analysis, Development Status, Segments and 2027...

Tissue regeneration: Reserve or reverse? – Science Magazine

A cross section of mouse small intestine, showing intestinal crypts and villi, is visualized with immunofluorescence microscopy (nuclei in red, and F-actin, which marks the cytoskeleton, in blue). Intestinal stem cells reside at the base of crypts, where they maintain cell turnover.

Tissues with high intrinsic turnover, such as the skin and intestinal lining, rely on resident stem cells, which generate all native cell types. Intestinal stem cells (ISCs) are highly sensitive to damage, although they recover quickly. It is unclear whether this recovery (i.e., regeneration) occurs from less sensitive pools of reserve stem cells (1) or whether ISC progeny undergo reverse differentiation into stem cells (2). Recent studies in diverse organs highlight that dedifferentiation of specified cell types is a pervasive and dominant means for tissue regeneration. The findings have broad implications because all tissues experience some cell attrition over a lifetime, and knowing how tissues replenish those losses may help in preventing or treating organ failure. Moreover, it remains unclear whether incomplete differentiation, a common feature of cancer, reflects normal tissue plasticity, and it is unclear whether stem cells that arise by dedifferentiation may spawn cancers.

ISCs expressing leucine-rich repeatcontaining G proteincoupled receptor 5 (Lgr5) lie at the bottom of small bowel crypts (3). In the course of homeostatic tissue turnover, their immediate progeny adopt alternative enterocyte or secretory fates, then fill the crypts with replicating progenitors that migrate away from ISCs. Cell division ceases at the crypt tops, where postmitotic cells begin a 3- to 5-day journey along intestinal villi. When ISCs sustain irreparable damage, some source in the crypt must regenerate new ISCs. Other adult epitheliasuch as airways, prostate, and liverare organized differently from the intestine and from each other (see the figure). These epithelia also restore cells lost by damage or attrition, even though at rest they turn over at least a hundred times more slowly than the intestinal lining.

Airway epithelial structure varies from trachea to small bronchioles, and distinct progenitors in different segments produce assorted secretory and ciliated cell types. In the lining of human and mouse upper airways, flat basal cells lie beneath a layer of columnar differentiated cells and adjacent to submucosal myoepithelial glands. Stem cell activity in normal tissue turnover maps to a subpopulation of keratin 5 (Krt5)expressing basal cells (4). The trachea and bronchi are vulnerable to diverse injuries, including targeted destruction of Krt5+ stem cells and pervasive mucosal damage from noxious inhalants or viruses.

Adult human and mouse prostate glands also contain columnar luminal and flat KRT5+ basal cells. Distinct unipotent progenitors maintain both populations, and castration induces massive luminal cell loss. Androgen reexposure restores prostate mass within weeks, which implies the presence of castration-resistant progenitors. However, an unequivocal stem cell pool has not been identified. The liver also has notable regenerative abilities after chemical or surgical injury. The emerging consensus is that this organ lacks a dedicated stem cell compartment and recovers from damage through dedifferentiation of mature hepatocytes and biliary cells (5, 6).

Stem cell activity in vivo is demonstrated most persuasively by introducing into a tissue a permanent color or fluorescent label whose expression depends on Cre recombinasemediated excision of a STOP cassette. When Cre activity is restricted to stem cells, all the progeny of those cells exclusively carry the label. ISCs and tracheal stem cells were thus identified because targeted Cre activity in LGR5+ or KRT5+ mouse cells labeled the respective full lineages (3, 4). Investigation of tissue regeneration requires ablation of a stem cell compartment, followed by tracking of the restored ability to produce sufficient numbers of all native stem cell progeny. The canon of tissue repair rests heavily on such lineage-tracing experiments, but one limitation is that Cre recombinase is not often confined to a single defined cell type. This challenge lies at the heart of competing models for tissue recovery after lethal cell injuries.

Dividing cells take up labels such as [3H]thymidine or fluorescent histone 2B and shed these labels as they replicate further or their daughters die. In the intestine, however, rare cells located near the fourth tier from the crypt base retain [3H]thymidine for weeks. Given once-popular ideas that stem cells must be few in number and retain one immortal DNA strand when they replicate, +4 label-retaining cells (LRCs) were described as ISCs. In support of that idea, lineage tracing from Bmi1, a locus thought to be restricted to nonreplicating +4 LRCs, elicited an ISC-like response in vivo (7).

Physiologic cell turnover and recovery from injury occur from different cellular sources in diverse epithelia (intestine, upper airway, and prostate gland). Homeostatic turnover is driven by the stem cell pool, and tissue restoration from injury occurs through transient expansion and dedifferentiation of specified mature cells.

To reconcile the evidence for ISC properties in both LGR5+ crypt base columnar cells (CBCs) and +4 LRCs, researchers postulated that abundant CBCs serve as frontline ISCs, whereas the smaller +4 LRC population contains dedicated reserves. Indeed, intestinal turnover is unperturbed when LGR5+ CBCs are ablated because other crypt cells' progeny continue to repopulate villi and an LGR5+ ISC compartment is soon restored (1). Multiple candidate markers of +4 LRCs that regenerate ISCs after injury have been proposed (8). Although these cells are too few to explain the typical scale and speed of ISC restoration, the prospect of two stem cell pools carried the additional allure of a sound adaptive strategy in a tissue that requires continuous self-renewal.

ISC differentiation is, however, not strictly unidirectional. Cre expression in absorptive or secretory cell types tags those cells selectively, but upon ablation of LGR5+ CBCs, the label appears throughout (9). These observations imply that differentiated daughter cells have reverted into ISCs. Moreover, Bmi1 expression was found to mark differentiated crypt endocrine cells (10), and putative +4 markers are expressed in many crypt cells including LGR5+ CBCs. Accordingly, when Cre is expressed from these loci, the traced lineage might simply reflect CBC activity in resting animals and reverse differentiation of crypt cells after ISC ablation. But is dedifferentiation a rare and physiologically inconsequential event or the predominant mode of stem cell recovery? Dedifferentiation may obviate the need to invoke a dedicated reserve population, or it is possible that ISC recovery may reflect both dedifferentiation and contributions from a reserve stem cell population.

To investigate these issues, researchers activated a fluorescent label in LGR5+ CBCs and waited for this label to pass into progeny cells before ablating CBCs (11). Thus, only the CBCs that recover by dedifferentiation should be labeled, and any cells arising from reserve ISCs should not. Nearly every restored crypt and CBC was fluorescent, with substantial contributions from both enterocytes and secretory cells (11). Cells captured early in the restorative process coexpressed mature-cell and ISC genes, which is compatible with recovery by dedifferentiation. Another study found that damaged ISCs are reconstituted wholly by the progeny of LGR5+ CBCs (8). Thus, dedifferentiation would seem to be the principal mode of ISC regeneration, and prior conclusions about +4 ISCs likely reflect unselective Cre expression.

Different tissues might deploy distinct regenerative strategies, and recent studies in mouse airway, prostate, intestinal, and liver epithelia provide insightful lessons. After ablation of KRT5+ airway stem cells, specified secretory and club cell precursors were found to undergo clonal multilineage expansion and accounted for up to 10% of restored KRT5+ cells in vivo (12). Chemical or viral damage was subsequently reported to induce migration and dedifferentiation of submucosal gland myoepithelial cells into the basal layer to reconstitute the surface lining, including KRT5+ stem cells (13). Thus, dedifferentiation into native stem cells occurs upon injury to both airway and intestinal linings in mice.

Single-cell RNA sequencing (scRNA-seq) analysis of mouse prostate glands recently revealed distinct gene expression profiles in 3% of luminal cells, which are more clonogenic than others, express putative stem cell markers, and hence qualify as a pool enriched for native stem-like cells (14). After androgen reexposure following castration, however, the scale and distribution of cell replication and the location of restored clones were incompatible with an origin wholly within that small pool. Rather, the principal source of gland reconstitution in vivo, including new KRT5+ basal cells, was the dominant population of differentiated luminal cells (14). These observations parallel those in the liver, where recovery of organ mass after tissue injury occurs by renewed proliferation of mature resting hepatocytes (5), abetted by expansion of bile duct cells that transdifferentiate into hepatocytes (6). Cell plasticity is thus widespread, whether tissues have or lack native stem cell compartments.

Reverse differentiation in the intestine, airways, and prostate gland was generally observed after near-total elimination of resident stem or luminal cells, an extreme and artificial condition. However, several observations suggest that this dedifferentiation reflects a physiologic process designed to maintain a proper cell census. Contact with a single KRT5+ airway stem cell prevents secretory and club cell dedifferentiation in vitro (12), and tracheal submucosal glands exhibit limited stem cell activity even in the absence of injury (13). Live imaging of intestinal crypts reveals continuous and stochastic exit from and reentry into the ISC compartment (15), implying that barriers for differentiation or dedifferentiation are inherently low. However, the primary purpose of dedifferentiating airway, intestinal, liver, and prostate cells is not to enable tissue recovery. Therefore, they should be regarded as facultative stem cells; that is, they have other physiologic functions and realize a latent stem cell capacity only under duress.

This distinction from reserve stem cells is not merely semantic. Emphasis in regenerative therapy research belongs on any cell population with restorative potential; in vivo findings now direct attention away from putative reserve cells and toward dedifferentiation as a common means for tissue recovery. The absence of dedicated reserves and the inherent cellular ability to toggle between stem and differentiated states also inform cancer biology. Because mutations realize oncogenic potential only in longlived cells, both frontline and reserve stem cells represent candidate sources of cancer, in contrast to differentiated cells, which are generally short-lived. However, oncogenic mutations that arise in differentiated cells could become fixed upon dedifferentiation, thus enabling tumor development.

Notably, stem cell properties and interconversion with their progeny are not stereotypic. ISCs divide daily into two identical daughters, whereas hematopoietic stem cell replication is infrequent and asymmetric. Severe loss of blood stem cells does not elicit substantial dedifferentiation and is rescued only by adoptive stem cell transfer. Immature secretory precursors dedifferentiate more readily than terminally mature airway cells (12), whereas fully differentiated cells fuel liver and prostate regeneration. Cell plasticity in each case is determined by local signals. Unknown factors from KRT5+ tracheal stem cells, for example, suppress secretory cell dedifferentiation (12), and specific factors secreted from the prostate mesenchyme stimulate luminal cell dedifferentiation (14). The intestinal mesenchyme probably senses ISC attrition to trigger tissue recovery, but the spatial and molecular determinants remain unknown. Outstanding challenges are to identify the signaling pathways that ensure a stable cell census and to harness diverse regenerative responses to ameliorate acute tissue injuries or prevent organ failure. Knowing the cellular basis for stem cell recovery in different contexts brings us closer to those goals.

Read this article:
Tissue regeneration: Reserve or reverse? - Science Magazine

Global Scaffold Technology Market Is Expected to Reach USD 2.16 billion by 2028 : Fior Markets – GlobeNewswire

February 18, 2021 13:00 ET | Source: Fior Markets

Newark, NJ, Feb. 18, 2021 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, theglobal scaffold technology market is expected to grow from USD 1.05 billion in 2020 and to reach USD 2.16 billion by 2028, growing at a CAGR of 9.45% during the forecast period 2021-2028.

The driving factors to the growth of the scaffold technology market are an increase in the requirement of organ transplantations and reconstruction procedures for the body across the globe. Scaffold technology is extensively utilized in order to imitate the construction of tissues. It is done in order to form a three-dimensional structure that enhances transplantation methods, resulting in an increase in the growth of the market. Scaffold technology plays an essential part in the regeneration and restoration of infected tissues in tissue engineering. Scaffold technology has various benefits in three-dimensional printing like the inclusion of growth factors, porosities, co-culture of multiple cells, and construction of composite geometries.

Tissue culture is depicted in a 3D arrangement with the help of scaffold technology. The technology is broadly used to provide cultural assays in three-dimension. Scaffold technology is a department of Tissue Engineering that overcomes the limitations made by two-dimensional cell culture. The three-dimensional cultural assays include cell to matrix interactions, cell migration assays, and cell to cell interactions. Scaffold technology mimics primary cells to use different tissues. It is done in order to mimic defective tissues from the scaffold biomaterials that are deeply porous. It works under cell biology that regulates three-dimensional cell structure.

An increase in the utilization of biomaterials that involves composites and polymers leads to the increase of fabrication of scaffold. It propels the market by encouraging the extensive use of scaffold technology in tissue engineering. Technological innovations and advancements related to reconstructive operational methods promote enhanced incorporation of scaffold technology. This promotes the usage of scaffold technology in the reconstructive processes. Moreover, continuous research and development programs in order to produce three-dimensional substrates result in an increased application of the technology in drug delivery. Also, inclination towards three-dimensional cell tissue culture from two-dimensional systems is expected to accelerate the growth of the market over the forecast period.


Key players operating in the global scaffold technology market include REPROCELL Inc., Tecan Trading AG, Molecular Matrix Inc., Xanofi, 3D Biotek LLC, Becton, Dickinson and Company, Thermo Fisher Scientific, Inc. and Merck KGaA. To gain a significant market share in the global scaffold technology market, the key players are now focusing on adopting strategies such as product innovations, mergers & acquisitions, recent developments, joint ventures, collaborations, and partnerships.

The nanofiber-based scaffolds segment is expected to show the highest share over the forecast periodThe type segment includes nanofiber based scaffolds, micropatterned surface microplates, polymeric scaffolds and hydrogels. The nanofiber-based scaffolds segment is expected to show the highest share in the global scaffold technology market over the forecast period. The nanofiber-based scaffolds have threadlike compositions that consist of pores. It is created with the help of the electro spinning method to promote the development of synthetic functional tissues in tissue engineering. Such synthetic tissues follow the typical extracellular pattern in tissues. It is beneficial in improving tissue engineering with the help of extracellular model of the tissue.

The stem cell therapy, regenerative medicine, and tissue engineering segment had the highest share of 56.04% in 2020 The application segment includes drug discovery, stem cell therapy, regenerative medicine, & tissue engineering. The stem cell therapy, regenerative medicine, and tissue engineering segment had the highest share of 56.04% in 2020 in the global scaffold technology market. The factors that contributed to the growth of the market are an extensive utilization of scaffold technology in colorectal surgeries, periodontology, abdominal wall repair, soft tissue tumor repair, aesthetic surgeries and wound healing. In order to improve the regeneration system, the blend of tissue repair scaffold along with antimicrobial agent is employed. Thus, it is anticipated to enhance reconstructive methods that include a huge probability of failure of reconstructed tissue. Hence, tissue-engineering in a controlled structure is a significant factor in the growth.

Browse full report with TOC at

Regional Segment Analysis of The Scaffold Technology Market

On the basis of geography, the global scaffold technology market is classified into North America, Europe, South America, Asia Pacific, and Middle East and Africa. North America had the largest share of 23.86% in 2020. The factors that contributed to the growth of the region are an increase in the investments in order to extend the applicability of scaffold technology, advanced healthcare structure as well as a growth in stem cell research along with regenerative medicine. Increasing investments by the prominent market players in order to increase the utilization of regenerative medicine and three-dimensional constructs in numerous applications has resulted in the growth of the market.

Request for Customization:

About the report: The global scaffold technology market is analyzed on the basis of value (USD billion). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

For Instant Purchase:

Customization of the Report:

The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.

Contact Us

Avinash D Head of Business Development Phone:+1-201-465-4211

To Know More Market Research Reports and Industry Analysis, Visit our Associate Website:

Related Reports Endocrine Testing Market - Epigenetics Drugs & Diagnostic Technologies Market - Blood Glucose Monitoring Systems Market - Capillary and Venous Blood Sampling Devices Market -

See the rest here:
Global Scaffold Technology Market Is Expected to Reach USD 2.16 billion by 2028 : Fior Markets - GlobeNewswire

Recombinant Growth Factors to Account for Over 45% of Overall Demand through 2031: Persistence Market Research – PRNewswire

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Cell culture supplements are the backbone of culturing methods and techniques in mammalian and microbial cell culture. Routinely performed cell-based assays and cell expansion processes require several growth factors to boost cell growth in the culture. Recombinant cell culture supplements serve an array of applications, such as stem cell research, drug discovery, oncology research, and regenerative medicine. Recombinant cell culture supplements and growth factors are used for culturing stem cells for expansion and differentiation into other cell types. Stem cell research is growing and adoption is increasing with time. Recombinant cell culture supplements such as albumin and transferrin are key components of mammalian cell culture. Increasing bioprocessing activities for production of novel biologics are likely to upswing the growth of the recombinant cell culture supplements market over the coming years.

These days, a majority of supplements used in research and manufacturing are produced using recombinant technology. Recombinant supplements play an important role in gene and cell therapy. Cell therapy requires to grow the cells outside the human body, i.e. in-vitro, and, recombinant cell culture supplements are inevitable for such applications. Due to rapid development within the biopharmaceutical industry, recombinant cell culture supplements are anticipated to witness significant demand through 2031.

According to a latest report published by Persistence Market Research, the global recombinant cell culture supplements market was valued at US$ 441 Mn in 2020, and is predicted to witness an impressive CAGR of over 6% during the forecast period (2021 2031).

Key Takeaways from Recombinant Cell Culture Supplements Market Study

Get the Sample PDF of the Report:

"Increasing drug discovery and preference for recombinant technology for bio- production will upswing the global recombinant cell culture supplements market," says an analyst of Persistence Market Research.

Get Full Access of Report:

Collaborations & Acquisitions Key Strategies amongst Market Players

Prominent players in the recombinant cell culture supplements market are firming their product ranges through acquisitions and reaching out to emerging markets. Increasing investments and manufacturing capacity expansion are expected to favour the growth the global market over the forecast period

Various players in the recombinant cell culture supplements market are focusing on growth strategies such as acquisitions and collaborations.

What Does the Recombinant cell culture supplements Market Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the recombinant cell culture supplements market in its latest study, presenting historical demand assessment of 2016 2020 and projections for 2021 2031, on the basis of product (recombinant growth factors, recombinant insulin,recombinant albumin, recombinant transferrin,recombinant trypsin, recombinant aprotinin, recombinant lysozyme, and others), application (stem cell therapy, gene therapy,bioprocess application,vaccine development, and others), source (animals, microorganisms, andhumans), and end user (academic and research institutes,biopharmaceutical companies,cancer research centers, and contract research centers (CROs)), across seven key regions of the world.

Browse Research Release at:

Browse End-to-end Market: IndustrialAutomation

Related Reports:

Cell Culture Media Market:

Cell Culture Freezing Market:

About Persistence Market Research


Persistence Market Research (PMR)is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At Persistence Market Research, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


Rajendra Singh Persistence Market Research U.S. Sales Office: 305 Broadway, 7th Floor New York City, NY 10007 +1-646-568-7751 United States USA - Canada Toll-Free: 800-961-035 Email: [emailprotected] Visit Our Website:

Content Source:

SOURCE Persistence Market Research Pvt. Ltd.

Originally posted here:
Recombinant Growth Factors to Account for Over 45% of Overall Demand through 2031: Persistence Market Research - PRNewswire

The Untapped Potential of Cell and Gene Therapy – Managed Markets Network

We can absolutely cut the number of cancer deaths down so that one day in our lifetimes it can be a rare thing for people to die of cancer, said Patrick Hwu, MD, president and CEO of Moffitt Cancer Center in Florida and among gene therapys pioneers. It still may happen here and there, but itll be kind of like people dying of pneumonia. Its like, He died of pneumonia? Thats kind of weird. I think cancer can be the same way.

The excitement returned in spades in 2017 when the FDA signed off on a gene-therapy drug for the first time, approving the chimeric antigen receptor (CAR) T-cell treatment tisagenlecleucel (Kymriah; Novartis) for the treatment of B-cell precursor acute lymphoblastic leukemia. At last, scientists had devised a way to reprogram a persons own T cells to attack tumor cells.

Were entering a new frontier, said Scott Gottlieb, MD, then the FDA Commissioner, in announcing the groundbreaking approval.

Gottlieb wasnt exaggerating. The growth in CAR T-cell treatments is exploding. Although only a handful of cell and gene therapies are on the market, FDA officials predicted in 2019 that the agency will receive more than 200 investigational new drug applications per year for cell and gene therapies, and that by 2025, it expects to have accelerated to 10 to 20 cell and gene therapy approvals per year.1

Essentially, you can kill any cancer cell that has an antigen that is recognized by the immune cell, Hwu said. The key to curing every single cancer, which is our goal, is to have receptors that can recognize the tumor but dont recognize the normal cells. Receptors recognizing and then attacking normal cells is what can cause toxicity.

Cell therapy involves cultivating or modifying immune cells outside the body before injecting them into the patient. Cells may be autologous (self-provided) or allogeneic (donor-provided); they include hematopoietic stem cells and adult and embryonic stem cells. Gene therapy modifies or manipulates cell expression. There is considerable overlap between the 2 disciplines.

Juliette Hordeaux, PhD, senior director of translational research for the University of Pennsylvanias gene therapy program, is cautious about the FDAs predictions, saying shed be thrilled with 5 cell and/or gene therapy approvals annually.

For monogenic diseases, there are only a certain number of mutations, and then well plateau until we reach a stage where we can go after more common diseases, Hordeaux said.

Safety has been the main brake around adeno-associated virus vector (AAV) gene therapy, added Hordeaux, whose hospitals program has the institutional memory of both Jesse Gelsingers tragic death during a 1999 gene therapy trial as well as breakthroughs by Carl June, MD, and others in CAR T-cell therapy.

Sometimes there are unexpected toxicity [events] in trials.I think figuring out ways to make gene therapy safer is going to be the next goal for the field before we can even envision many more drugs approved.

In total, 3 CAR T-cell therapies are now on the market, all targeting the CD19 antigen. Tisagenlecleucel was the first. Gilead Sciences received approval in October 2017 for axicabtagene ciloleucel (axi-cel; Yescarta), a CAR T-cell therapy for adults with large B-cell non-Hodgkin lymphoma. Kite Pharma, a subsidiary of Gilead, received an accelerated approval in July 2020 for brexucabtagene autoleucel (Tecartus) for adults with relapsed or refractory mantle cell lymphoma.

On February 5, 2021, the FDA approved another CD19-directed therapy for relapsed/refractory large B-cell lymphoma, lisocabtagene maraleucel (liso-cel; JCAR017; Bristol Myers Squibb). The original approval date was missed due to a delay in inspecting a manufacturing facility (see related article).

Idecabtagene vicleucel (ide-cel; bb2121; Bristol Myers Squibb) is under priority FDA review, with a decision expected by March 31, 2021. The biologics license application seeks approval for ide-cel, a B-cell maturation antigendirected CAR therapy, to treat adult patients with multiple myeloma who have received at least 3 prior therapies.2

The number of clinical trials evaluating CAR T-cell therapies has risen sharply since 2015, when investigators counted a total of 78 studies registered on the website. In June 2020, the site listed 671 trials, including 357 registered in China, 256 in the United States, and 58 in other countries.3

Natural killer (NK) cells are the research focus of Dean Lee, MD, PhD, a physician in the Division of Hematology and Oncology at Nationwide Childrens Hospital. He developed a method for consistent, robust expansion of highly active clinical-grade NK cells that enables repeated delivery of large cell doses for improved efficacy. This finding led to several first-in-human clinical trials evaluating adoptive immunotherapy with expanded NK cells under an FDA Investigational New Drug application. He is developing both genetic and nongenetic methods to improve tumor targeting and tissue homing of NK cells. His eff orts are geared toward pediatric sarcomas.

The biggest emphasis over the past 20 to 25 years has been cell therapy for cancer, talking about trying to transfer a specific part of the immune system for cells, said Lee, who is also director of the Cellular Therapy and Cancer Immunology Program at Nationwide Childrens Hospital, at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital, and at the Richard J. Solove Research Institute.

The Pivot Toward Treating COVID-19 and Other Diseases

However, Lee said, NKs have wider potential. This is kind of a natural swing back. Now that we know we can grow them, we can reengineer them against infectious disease targets and use them in that [space], he said.

Lee is part of a coronavirus disease 2019 (COVID-19) clinical trial, partnering with Kiadis, for off-the-shelf K-NK cells using Kiadis proprietary platforms. Such treatment would be a postexposure preemptive therapy for treating COVID-19. Lee said the pivot toward treating COVID-19 with cell therapy was because some of the very early reports on immune responses to coronavirus, both original [SARS-CoV-2] and the new [mutation], seem to implicate that those who did poorly [overall] had poorly functioning NK cells.

The revolutionary gene editing tool CRISPR is making its initial impact in clinical trials outside the cancer area. Its developers, Jennifer Doudna, PhD, and Emmanuelle Charpentier, PhD, won the Nobel Prize in Chemistry 2020.

For patients with sickle cell disease (SCD), CRISPR was used to reengineer bone marrow cells to produce fetal hemoglobin, with the hope that the protein would turn deformed red blood cells into healthy ones. National Public Radio did a story on one patient who, so far, thanks to CRISPR, has been liberated from the attacks of SCD that typically have sent her to the hospital, as well from the need for blood transfusions.4

Its a miracle, you know? the patient, Victoria Gray of Forest, Mississippi, told NPR.

She was among 10 patients with SCD or transfusion-dependent beta-thalassemia treated with promising results, as reported by the New England Journal of Medicine.5 Two different groups, one based in Nashville, which treated Gray,5 and another based at Dana-Farber Cancer Institute in Boston,6 have reported on this technology.

Stephen Gottschalk, MD, chair of the department of bone marrow transplantation and cellular therapy at St Jude Childrens Research Hospital, said, Theres a lot of activity to really explore these therapies with diseases that are much more common than cancer.

Animal models use T cells to reverse cardiac fibrosis, for instance, Gottschalk said. Using T cells to reverse pathologies associated with senescence, such as conditions associated with inflammatory clots, are also being studied.

Hordeaux said she foresees AAV being used more widely to transmit neurons to attack neurodegenerative diseases.

The neurons are easily transduced by AAV naturally, she said. AAV naturally goes into neurons very efficiently, and neurons are long lived. Once we inject genetic matter, its good for life, because you dont renew neurons.

Logistical Issues

Speed is of the essence, as delays in producing therapies can be the difference between life and death, but the approval process takes time. The process of working out all kinks in manufacturing also remains a challenge. Rapid production is difficult, too, because of the necessary customization of doses and the need to ensure a safe and effective transfer of cells from the patient to the manufacturing center and back into the patient.7

Other factors that can slow down launches include insurance coverage, site certification, staff training, reimbursement, and patient identification. The question of how to reimburse has not been definitively answered; at this point, insurers are being asked to issue 6- or even 7-figure payments for treatments and therapies that may not work.8

CAR T, I think, will become part of the standard of care, Gottschalk said. The question is how to best get that accomplished. To address the tribulations of some autologous products, a lot of groups are working with off -the-shelf products to get around some of the manufacturing bottlenecks. I believe those issues will be solved in the long run.


1. Statement from FDA Commissioner Scott Gottlieb, MD, and Peter Marks, MD, PhD, director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies. News release. FDA website. January 15, 2019. Accessed January 13, 2021.

2. Bristol Myers Squibb provides regulatory update on lisocabtagene maraleucel (liso-cel). News release. Bristol Myers Squibb; November 16, 2020. Accessed January 11, 2021.

3. Wei J, Guo Y, Wang Y. et al. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. Published online September 30, 2020. doi:10.1038/s41423-020-00555-x

4. Stein R. CRISPR for sickle cell diseases shows promise in early test. Public Radio East. November 19, 2019. Accessed January 11, 2021.

5. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and -Thalassemia. N Engl J Med. Published online December 5, 2020. DOI: 10.1056/NEJMoa2031054

6. Esrick EB, Lehmann LE, Biffi A, et al. Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. N Engl J Med. Published online December 5, 2020. doi:10.1056/NEJMoa2029392

7. Yednak C. The gene therapy race. PwC. February 5, 2020. Accessed January 11, 2021.

8. Gene therapies require advanced capabilities to succeed after approval. PwC website. Accessed January 11, 2021.

Read the original post:
The Untapped Potential of Cell and Gene Therapy - Managed Markets Network

Century Therapeutics Significantly Expands Capabilities with New Operational, Laboratory and Manufacturing Facilities in Pennsylvania and New Jersey -…

PHILADELPHIA, Feb. 17, 2021 /PRNewswire/ --Century Therapeutics, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, today announced a significant expansion of its operational and laboratory space in Philadelphia, as well as progress on its manufacturing facility in Branchburg, NJ, paving the way for a strong technical foundation as the company scales up its in-house research and development capabilities.

The company is expanding its presence in uCity Square, opening 17,000 square feet of mixed office and laboratory space at 3624 Market Street, an additional 5,000 square feet of space at 3711 Market Street and has signed a lease for 25,000 square feet at 3535 Market Street all within steps of the current headquarters at 3675 Market Street.Century has also committed to 33,000 square feet in the One uCity life sciences development currently under construction in the same burgeoning region of the city. "We are excited to expand our footprint within the heart of Philadelphia which has emerged as an epicenter of the growing cell and gene therapy field," said Lalo Flores, PhD, Chief Executive Officer of Century Therapeutics. "This new space will not only boost community vitality and fuel the local economy, but it will also enable us to accelerate development of our genetically engineered, universal iPSC-derived immune effector cell products including iNK and iT cells and ultimately reach more cancer patients."

Century has also signed a lease to build their ownin-house cGMP manufacturing facility in Branchburg, NJ, with the goal of being operational later this year. Construction of the 53,000 square foot space has already begun, with preliminary plans underway for a second phase expansion in support of later clinical stage programs. This capability will supplement existing privileged access to the Fujifilm Cellular Dynamics (FCDI) facilities and power a rapidly growing pipeline of cellular products. "Adding in-house manufacturing capabilities will enable us to generate our pipeline with homogenous products that can be manufactured and scaled in a cost-effective manner," adds Dr. Flores. "It is a critical step in our strategic plan to accelerate product iteration, provide additional optionality and de-risk technical execution."

In addition to the Pennsylvania and New Jersey locations, Century has a laboratory in Hamilton, Ontario specifically focused on targeting glioblastoma, and recently opened a Seattle-based innovation hub to help advance the company's novel iPSC platform and support the continued pipeline growth and development.

Century Therapeutics plans to leverage this expansion to build upon their existing expertise in gene editing, protein engineering and cell manufacturing to become a fully integrated biotech producing optimized cell therapies through highly intentional, selective targeting and thoughtful design.The company's iPSC-derived CAR-expressing NK cells and T cells are expected to enter clinical trials for a range of hematological and solid cancers in 2022.

About Century Therapeutics Century Therapeutics is harnessing the power of stem cells to develop curative cell therapy products for cancer that overcome the limitations of first-generation cell therapies. Our genetically engineered, universal iPSC-derived immune effector cell products (iNK, iT) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care. For more information, please visit

SOURCE Century Therapeutics

Read more from the original source:
Century Therapeutics Significantly Expands Capabilities with New Operational, Laboratory and Manufacturing Facilities in Pennsylvania and New Jersey -...

Cell Therapy Processing Market To Grow Value $12062 Million By 2026 | Latest Research Report –

Pune, Maharashtra, India, February 17 2021 (Wiredrelease) Allied Analytics :According to the report published by Allied Market Research, the global The cell therapy processing market was valued at $1,695 million in 2018, and is projected to reach $12,062 million by 2026, registering a CAGR of 27.8% from 2019 to 2026.

Cell Therapy Processing Market by Offering Type (Products, Services, and Software), and Application (Cardiovascular Devices, Bone Repair, Neurological Disorders, Skeletal Muscle Repair, Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 20192026.

Prime determinants of growth

Increase in the incidence of cardiovascular diseases and surge in the demand for chimeric antigen receptor (CAR) cell therapy propel the global cell therapy processing market. However, poor demand from underdeveloped countries hinders the market growth. On the other hand, emerging markets are expected offer lucrative opportunities in the near future.

Request Sample Report at:

The skeletal muscle repair segment to maintain its lions share in terms of revenue by 2026

Based on application, the skeletal muscle segment accounted for the largest market share of the global cell therapy processing market in 2018, accounting for more than one-fifth of the total market share in 2018. Moreover, the neurological disorders segment is estimated to grow at the highest CAGR of 29.7% from 2019 to 2026. The use of fetal neural tissue for cell therapy presented the first unambiguous proof that such grafts can be used to grow, evolve, and recover functional defects in rodents to varying degrees, which boosts the growth of the segment.

The growth of the cell therapy processing market is attributed to increase in the incidence of cardiovascular diseases. Furthermore, rise in the demand for chimeric antigen receptor (CAR) t cell therapy, and increase in the development of stem cell therapy approaches globe are the other factors that contribute to the growth of the cell therapy processing market.

Based on offering type, the market is categorized into products, services, and software. Presently, products dominates the cell therapy processing market, and is anticipated to continue this trend over the forecast period. The key factors that driving the market growth are rise in the incidence of cardiovascular diseases, increase in demand for cell therapy processing, surge in adoption of allogeneic cell therapy, and introduction of novel technologies for cell therapy processing drives the market growth of this segment.

North Americato maintain its dominance during the forecast period

Based on region,North Americaaccounted for the highest market share in terms of revenue, accounting for nearly two-fifths of the global cell therapy processing market in 2018, and is estimated to maintain its dominance during the forecast period. This is attributed to presence of well-established healthcare infrastructure, higher buying power, and surge adoption of advanced medical therapies. In addition, rise in prevalence of osteoporosis coupled with surge in geriatric population fuels the growth of the market in this region. Moreover,Asia-Pacificis expected to maintain the highest CAGR of 29.0% from 2019 to 2026, owing to presence of huge patient base, increase in research and development expenditure, and surge in usage of cell therapy processing products.

For Purchase Enquiry at:

Leading market players

Invitrx Inc.

Cell Therapies Pty Ltd

Lonza Ltd

Merck & Co., Inc (FloDesign Sonics)

NantWorks, LLC

Neurogeneration, Inc.

Novartis AG

Plasticell Ltd.

Regeneus Ltd

StemGenex, Inc.

North America accounted for approximately one-half of the global cell therapy processing market share in 2018 and is expected to remain dominant throughout the forecast period. This was attributed to increase in the popularity of stem cell research, rise in patient awareness towards stem cell therapies, and well developed healthcare infrastructure. On the other side, Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, the developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare.

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of Market Research Reports and Business Intelligence Solutions. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.


David Correa 5933 NE Win Sivers Drive #205,Portland, OR97220 United States USA/Canada(Toll Free):+1-800-792-5285, +1-503-894-6022, +1-503-446-1141 UK:+44-845-528-1300 Hong Kong:+852-301-84916 India(Pune):+91-20-66346060 Fax:+1(855)550-5975 Web: Follow Us on LinkedIn:

This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at

Excerpt from:
Cell Therapy Processing Market To Grow Value $12062 Million By 2026 | Latest Research Report -

Global Stem Cell Therapy Market 2020 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2025 KSU | The Sentinel… has presented updated research report titled Global Stem Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 which presents vital answers and interpretations concerning market growth and developments in the market. The report contains insightful information like market share, market size, and growth rate, as well as several challenges and ingrained threats and limitations that have interrupted normal growth prognosis in global Stem Cell Therapy market. The report analyzes the segment expected to dominate the industry and market.This market report includes quantitative and qualitative estimation by industry experts, the contribution from industry across the value chain. The report gives information about the supply and demand situation, the competitive scenario, market opportunities, and the threats faced by key players.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Competitive Intelligence:

The leading players are covered in the global Stem Cell Therapy market report with product description, business outline, as well as production, future demand, company profile, product portfolio, product/service price, capacity, sales, and cost. So the entire information related to the company concerning the specific product and in-depth information of collaborations and all other essential information is added in the research report.


Report has been segmented into geographical segmentation, key players, key topics industry value and demand analysis and forecast and gives comprehensive investigation.The report provides knowledge of the key product segments and their future by having complete insights of market and by making in-depth analysis of market segments. Report includes supply-demand statistics, and segments that constrain the growth of an industry. It also includes raw materials used and manufacturing process of global Stem Cell Therapy market.

All top players actively involved in this industry are as follows: Osiris Therapeutics, Molmed, JCR Pharmaceutical, NuVasive, Anterogen, Chiesi Pharmaceuticals, Medi-post, Pharmicell, Takeda (TiGenix)

The report highlights product types which are as follows:Autologous, Allogeneic

The report highlights top applications which are as follows:Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, Others

Promising regions & countries mentioned in the global Stem Cell Therapy market report:North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

Market By Manufacturing Cost Analysis:

The study report includes key raw materials analysis, the price trend of key raw materials, key suppliers of raw materials, market concentration rate of raw materials, the proportion of manufacturing cost structure, and manufacturing process analysis. Moreover, the report evaluates the product pricing, production capacity, demand, supply, as well as the historical performance of the global Stem Cell Therapy market.


Report Offerings:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (, who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: Web:

See the rest here:
Global Stem Cell Therapy Market 2020 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2025 KSU | The Sentinel...

Humanized Mouse and Rat Model Market: Increased development of monoclonal antibodies and improved healthcare to drive the market – BioSpace

Humanized Mouse and Rat Model Market: Introduction

Request Brochure of Report -

Key Drivers, Restrains, and Opportunities of Global Humanized Mouse and Rat Model Market

Request for Analysis of COVID-19 Impact on Humanized Mouse and Rat Model Market -

North America to Capture Major Share of Global Humanized Mouse and Rat Model Market

Pre Book Humanized Mouse and Rat Model Market Report at

Read more information here:

Key Players Operating in Global Humanized Mouse and Rat Model Market

The global humanized mouse and rat model market is highly consolidated due to the presence of key players. A large number of manufacturers hold a major share in their respective regions. Growth strategies adopted by leading players are likely to drive the global humanized mouse and rat model market. For instance, in February 2020, Taconic Biosciences, a global pioneer in offering drug discovery animal model solutions, announced that its humanized immune system mice models were presently being developed in Europe. Local manufacturing makes it easier for Europe-based drug discovery researchers to access this vital oncology research instrument.

Ask for Discount :

Major players operating in the global humanized mouse and rat model market are listed below:

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.


Mr. Rohit Bhisey Transparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453



Read more from the original source:
Humanized Mouse and Rat Model Market: Increased development of monoclonal antibodies and improved healthcare to drive the market - BioSpace

Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings – PRNewswire

HOUSTON, Feb. 16, 2021 /PRNewswire/ --Iterion Therapeutics, Inc. ("Iterion"), a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that it has raised $17 million USD in a Series B financing led by Lumira Ventures, with the participation of existing investors, including Sant Ventures, as well as new investors Venture Investors, GPG Ventures, and Viva BioInnovator.

Iterion plans to utilize the proceeds from this financing to advance the development of its lead clinical candidate, Tegavivint, a novel, potent and selective nuclear beta-catenin inhibitor.Tegavivint is currently being investigated in a Phase 1/2a clinical trial in patients with desmoid tumors, which are rare, non-metastasizing sarcomas that overexpress nuclear beta-catenin. Iterion has received Orphan Drug Designation for Tegavivint to treat desmoid tumors, a disease for which there are no FDA approved therapies.

In addition to desmoid tumors, Iterion is preparing to initiate clinical programs in 2021 to investigate Tegavivint in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers, including sarcomas, lymphoma and other solid tumors. These cancers are often characterized by nuclear beta-catenin overexpression, providing potential high-value target expansions for Tegavivint.

"We envision incredible potential therapeutic benefits associated with Tegavivint, and are excited to support the Iterion team in its exploration of multiple clinical development opportunities for this potentially groundbreaking therapeutic," said Benjamin Rovinski, Ph.D., Managing Director at Lumira Ventures. "2021 is expected to be a pivotal year for Iterion as the company anticipates initiating clinical trials in AML, NSCLC and pediatric cancers, all indications in which nuclear beta-catenin signaling plays a role. By pursuing a novel mechanism of action, we believe Tegavivint has the potential to overcome challenges faced by prior drugs targeting this pathway."

Nuclear beta-catenin is a highly-studied oncology target associated with numerous cancer types. Tegavivint is unique among nuclear beta-catenin inhibitors in that it binds to TBL1 (Transducin Beta-like Protein One), a novel downstream target in the Wnt-signaling pathway. As such, Tegavivint enables silencing of Wnt-pathway gene expression without affecting other necessary Wnt/beta-catenin functions in the cell membrane, thus avoiding toxicity issues common to other drugs in this pathway.

"We are grateful to have the confidence of investors, including Lumira Ventures, Sant Ventures and others, that appreciate Tegavivint's potential to treat a host of cancers," said Rahul Aras, Ph.D., CEO of Iterion."Nuclear beta-catenin has historically been considered an 'undruggable' oncology target with prior inhibitors having been plagued by toxicity issues, greatly limiting their therapeutic use. Research suggests that these toxicity concerns can be negated by targeting TBL1, a novel downstream target in the Wnt-signaling pathway necessary for beta-catenin's oncogenic activity. This is precisely Tegavivint's mechanism of action and why we believe the technology holds such substantial promise."

Dr. Aras continued, "With the Series B funding, Iterion has the potential to significantly expand our clinical footprint through completion of our ongoing desmoid tumor study and initiate clinical trials in 2021 to investigate Tegavivint in AML, NSCLC, and certain pediatric cancers."

About Iterion TherapeuticsIterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics. The company's lead product, Tegavivint, is a potent and selective inhibitor of nuclear beta-catenin, a historically "undruggable" oncology target implicated in cell proliferation, differentiation, immune evasion and stem cell renewal. Research demonstrating potent anti-tumor activity in a broad range of pre-clinical models indicate that Tegavivint has the potential for clinical utility in multiple cancer types. Tegavivint is currently the subject of a Phase 1/2a clinical trial in patients with progressive desmoid tumors. Iterion is also pursuing clinical programs in additional cancers where nuclear beta-catenin signaling has been shown to play a role, including acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers, including sarcomas, lymphoma and other solid tumors. Iterion is the recipient of an up to $15.9 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information on Iterion, please visit or follow the Company on Twitter and Linkedin.

Tiberend Strategic Advisors, Inc.Ingrid Mezo (Media)646-604-5150 [emailprotected]

SOURCE Iterion Therapeutics

See more here:
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings - PRNewswire